Successful trials for Sandoz and Lannett biosimilars

Biosimilars/Research | Posted 30/09/2022 comments 0
Clinical Trials 2 V13K29

On 19 September 2022, Sandoz announced positive results following its ROSALIA I/III clinical trial study for its proposed biosimilar denosumab. This follows the August announcement that Lannett Com...

More >
FORO LATINOAMERICANO DE ESTA SEMANA
02 AA010638
Nomenclature of biologicals and biosimilars in Peru
Posted 20/05/2022

This article, the last in a series on the nomenclature of biological and biosimilar med...

Brazil flag V13C03
Brazilian market of biosimilars
Posted 20/05/2022

As the largest country in South America, Brazil is an important market for the pharmace...

Guidance V13F21
WHO revised guidelines for biosimilars: scientific background
Posted 08/07/2022

A study carried out by Kurki P et al. in 2022 reviewed the current clinical experi...

Home/Non‐Biological Complex Drugs
Liposome V15L11

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidance...

More >

Generics

Pricing and reimbursement of medicines in Canada
Generics/Research | Posted 02/09/2022
Pharmaceutical manufacturing companies in Brazil
Generics/General | Posted 26/08/2022
Pharmaceutical companies in Argentina
Generics/General | Posted 08/07/2022

Biosimilars

Successful trials for Sandoz and Lannett biosimilars
Biosimilars/Research | Posted 30/09/2022
EMA calls for biosimilar interchangeability across the EU
Biosimilars/General | Posted 23/09/2022
EC approves bevacizumab biosimilar Vegzelma
Biosimilars/News | Posted 23/09/2022